Welcome to our dedicated page for Hyperliquid Strategies SEC filings (Ticker: PURR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to SEC filings for Hyperliquid Strategies Inc (NASDAQ: PURR), a company that describes itself as a digital asset treasury business focused on accumulating HYPE, the native token of the Hyperliquid blockchain. While specific filings may vary over time, SEC documents are the primary source for detailed information about the company’s operations, risks, and capital structure.
In its public descriptions, Hyperliquid Strategies Inc highlights activities such as staking, yield optimization, and active engagement in the Hyperliquid ecosystem as part of its approach to generating returns from HYPE. When available, core filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q can provide additional context on how these activities are reflected in the company’s financial statements, risk factors, and management discussion.
For investors tracking PURR, SEC filings can also shed light on matters such as stock repurchase programs authorized by the Board of Directors, the company’s use of cash in connection with its HYPE-focused strategy, and other capital allocation decisions. Current reports on Form 8-K, when filed, may discuss material events, including changes to repurchase authorizations or other significant corporate actions.
Stock Titan enhances access to these documents with AI-powered summaries
LEIBOWITZ LAWRENCE E reported acquisition or exercise transactions in this Form 4 filing.
Hyperliquid Strategies Inc director Lawrence E. Leibowitz received an equity grant rather than cash compensation. On July 1, 2026, he was awarded 2,117 shares of Common Stock at $0.00 per share, electing to take pay in stock under the company’s 2025 Equity Incentive Plan.
After this grant, he directly holds 85,980 shares of Hyperliquid Strategies Inc common stock. This was a non-cash, compensation-related award, not an open‑market purchase or sale.
Rosengren Eric S reported acquisition or exercise transactions in this Form 4 filing.
Hyperliquid Strategies Inc director Eric S. Rosengren increased his direct holdings through an equity compensation grant. On July 1, 2026, he received 4,764 shares of common stock at $0.00 per share as compensation in lieu of cash under the 2025 Equity Incentive Plan. After this grant, he directly holds 76,800 common shares, and no derivative securities are reported in this filing.
Hyperliquid Strategies Inc director Thomas C. King received a grant of 4,764 shares of common stock on July 1, 2026. The filing states he elected to take this equity instead of cash under the company’s 2025 Equity Incentive Plan, so no purchase occurred in the market.
After this award, King directly holds a total of 76,800 common shares. This is a routine compensation-related acquisition, reflecting additional equity-based pay rather than a discretionary open-market trade.
Hyperliquid Strategies Inc director Nailesh Bhatt reported receiving a stock-based compensation award. On July 1, 2026, he acquired 1,588 shares of Common Stock at $0.00 per share, classified as a grant or award rather than an open-market trade.
According to the filing, Bhatt elected to receive these shares as compensation in lieu of cash under Hyperliquid Strategies’ 2025 Equity Incentive Plan. Following this award, he directly holds 46,914 shares of the company’s common stock, reflecting increased equity-based compensation and no reported sales or dispositions in this filing.
Hyperliquid Strategies Inc. updated compensation arrangements for its chief operating officer and chief executive officer. The company entered an Executive Placement Agreement with SBR Limited, which provides the services of COO Jeroen Nieuwkoop, including $400,000 annual base pay, a target cash bonus equal to 100% of base pay, and eligibility for annual equity awards with a target value of $1,000,000 under the 2025 Equity Incentive Plan.
The COO agreement also grants two initial restricted stock unit awards, each with a target fair value of $1,000,000, and provides severance, health benefit reimbursements, and accelerated equity vesting if terminated without cause or for good reason, with enhanced benefits during a change in control period. Separately, a First Amendment to CEO David Schamis’ employment agreement raises his base salary to $600,000, sets a 100% target bonus, and provides for annual equity awards targeted between $2,000,000 and $3,000,000 per year starting with the fiscal year beginning July 1, 2026.
Hyperliquid Strategies Inc. has filed an amended Form S-1 to register up to 35,156,660 shares of common stock for potential resale by Rorschach Advisors LLC. These include 7,761,860 Advisor Issued Shares and up to 27,394,800 Advisor Warrant Shares issuable upon exercise of Advisor Warrants.
The Advisor Warrants are exercisable for five years after the December 2, 2025 closing of the business combination with Sonnet BioTherapeutics, at exercise prices of $9.375, $12.50 and $18.75 for equal portions. The company will not receive proceeds from resales and is unlikely to receive significant cash from warrant exercises because a cashless exercise feature is available.
The filing notes that if all Advisor Shares are issued and sold, they would represent about 17.9% of outstanding common stock as of June 15, 2026, which could pressure the PURR share price. The prospectus also emphasizes the company’s HYPE token–focused treasury strategy and extensive related regulatory and market risks.
Nieuwkoop Jeroen reported acquisition or exercise transactions in this Form 4 filing.
Hyperliquid Strategies Inc reported that SBR Limited, a Hong Kong company controlled by Chief Operating Officer Jeroen Nieuwkoop, received 421,623 restricted stock units (RSUs) of common stock as of June 23, 2026 under an executive placement agreement.
Of these RSUs, 271,923 are scheduled to vest ratably on an annual basis over three years starting on December 2, 2026, and 149,700 are scheduled to vest ratably over three years starting on May 5, 2027. Following the transactions, Nieuwkoop also holds 31,840 common shares directly and 421,623 common shares indirectly through SBR Limited.
Hyperliquid Strategies Inc has filed an amended Form S-1 to register up to 35,156,660 shares of common stock for potential resale by Rorschach Advisors LLC. This includes 7,761,860 issued shares and 27,394,800 shares issuable upon exercise of Advisor Warrants with tiered strike prices.
The company will not receive proceeds from any resale of these shares and is unlikely to receive cash from warrant exercises because the warrants allow cashless exercise. If all Advisor Warrant Shares are issued and sold, the Advisor Shares would equal about 17.9% of outstanding stock as of June 15, 2026, creating a significant potential overhang.
Hyperliquid Strategies is now a holding company whose main assets are large HYPE token holdings and cash. At closing of its prior business combination, it held approximately $580 million in HYPE tokens (valued at $46.372 per token under the deal) and about $310 million in cash. The prospectus highlights extensive risks tied to HYPE’s extreme price volatility, evolving digital‑asset regulation, custody and security vulnerabilities, and potential exposure to the corporate alternative minimum tax from fair‑value accounting of its crypto holdings.
Hyperliquid Strategies Inc has filed a resale registration covering up to 35,156,660 shares of common stock for Rorschach Advisors LLC, the selling securityholder. The shares consist of 7,761,860 Advisor Issued Shares and up to 27,394,800 Advisor Warrant Shares issuable upon exercise of Advisor Warrants.
The company will not receive proceeds from the resale of these shares. Although it could receive cash from warrant exercises, the warrants include a cashless exercise feature that makes cash exercises unlikely. If all Advisor Warrant Shares are issued and sold, the Advisor Shares would represent approximately 20.5% of outstanding common stock as of May 19, 2026, creating a potential overhang on the stock.
The business now operates as a holding company owning HYPE tokens and cash following its business combination with Sonnet BioTherapeutics and Rorschach I LLC, and pursues a cryptocurrency treasury strategy centered on HYPE. The prospectus highlights significant risks tied to HYPE’s price volatility, evolving digital-asset regulation, potential investment company and tax treatment issues, and custody and cybersecurity risks around its large HYPE holdings.
Hyperliquid Strategies Inc supplements its prospectus to register up to 160,000,000 shares of Common Stock for sale from time to time by Chardan Capital Markets LLC. The supplement, dated May 8, 2026, also attaches the Company’s Form 10-Q for the quarter ended March 31, 2026.
The Form 10-Q shows the Company holding cash and cash equivalents of $113,064 and HYPE digital assets with a reported fair value of $689,045 (amounts presented in the filing). The filing reports net income of $152,510 for the three months ended March 31, 2026 and states 134,621,571 shares outstanding as of May 7, 2026. The prospectus supplement should be read with the December 2, 2025 prospectus.